Intracellular Cost Of Revenue vs Income Before Tax Analysis

ITCI Stock

USD 85.65 0.94 1.09%

Intracellular financial indicator trend analysis is infinitely more than just investigating Intracellular Th recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Intracellular Th is a good investment. Please check the relationship between Intracellular Cost Of Revenue and its Income Before Tax accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Intracellular Th. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

Cost Of Revenue vs Income Before Tax

Cost Of Revenue vs Income Before Tax Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Intracellular Th Cost Of Revenue account and Income Before Tax. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Intracellular's Cost Of Revenue and Income Before Tax is -0.11. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Income Before Tax in the same time period over historical financial statements of Intracellular Th, assuming nothing else is changed. The correlation between historical values of Intracellular's Cost Of Revenue and Income Before Tax is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Intracellular Th are associated (or correlated) with its Income Before Tax. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Before Tax has no effect on the direction of Cost Of Revenue i.e., Intracellular's Cost Of Revenue and Income Before Tax go up and down completely randomly.

Correlation Coefficient

-0.11

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Intracellular Th income statement and represents the costs associated with goods and services Intracellular provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on Intracellular income statement and is an important metric when analyzing Intracellular Th profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.

Most indicators from Intracellular's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Intracellular Th current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Intracellular Th. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

As of now, Intracellular's Selling General Administrative is increasing as compared to previous years. The Intracellular's current Tax Provision is estimated to increase to about 667.8 K, while Issuance Of Capital Stock is projected to decrease to 0.00.

	2021	2022	2023	2024 (projected)
Net Interest Income	1.6M	7.4M	20.3M	21.4M
Interest Income	1.6M	7.4M	20.3M	21.4M

Net Interest Income Interest Income

Intracellular fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Accounts Payable	Cash	Other Assets	Common Stock Shares Outstanding	Short Term Investments	Other Current Assets	Total Liab	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Retained Earnings Total Equity
Total Assets		0.59	0.63	0.99	0.78	0.66	0.72	0.02	0.9	0.93	0.74	0.67	0.31	0.27	-0.45	0.92	0.65	0.67	-0.61	-0.79	0.55	0.33	0.98	0.54	0.94	-0.82
Other Current Liab	0.59		1.0	0.53	0.59	0.59	0.73	-0.2	0.7	0.36	0.93	0.98	0.38	0.21	-0.76	0.78	0.49	0.49	-0.89	-0.91	0.95	0.89	0.49	0.98	0.68	-0.85
Total Current Liabilities	0.63	1.0		0.57	0.65	0.65	0.77	-0.18	0.75	0.4	0.94	0.99	0.38	0.25	-0.75	0.8	0.54	0.52	-0.9	-0.94	0.94	0.85	0.53	0.96	0.73	-0.89
Total Stockholder Equity	0.99	0.53	0.57		0.74	0.61	0.66	0.05	0.86	0.96	0.69	0.61	0.27	0.24	-0.41	0.92	0.6	0.67	-0.55	-0.74	0.5	0.28	0.99	0.49	0.9	-0.77
Other Liab	0.78	0.59	0.65	0.74		0.87	0.74	0.21	0.89	0.66	0.62	0.71	0.34	0.37	-0.43	0.71	0.71	0.59	-0.61	-0.8	0.59	0.33	0.74	0.47	0.89	-0.83
Accounts Payable	0.66	0.59	0.65	0.61	0.87		0.73	0.27	0.82	0.51	0.62	0.67	0.24	0.32	-0.53	0.6	0.51	0.63	-0.66	-0.74	0.48	0.32	0.61	0.47	0.78	-0.76
Cash	0.72	0.73	0.77	0.66	0.74	0.73		-0.18	0.89	0.45	0.81	0.8	0.28	0.3	-0.69	0.66	0.69	0.62	-0.9	-0.85	0.65	0.43	0.6	0.68	0.85	-0.86
Other Assets	0.02	-0.2	-0.18	0.05	0.21	0.27	-0.18		-0.03	0.15	-0.25	-0.19	-0.09	-0.12	-0.02	-0.02	-0.21	0.09	0.18	0.14	-0.23	-0.18	0.09	-0.25	0.01	0.11
Common Stock Shares Outstanding	0.9	0.7	0.75	0.86	0.89	0.82	0.89	-0.03		0.73	0.82	0.8	0.28	0.45	-0.53	0.82	0.77	0.67	-0.76	-0.9	0.65	0.38	0.83	0.62	0.98	-0.93
Short Term Investments	0.93	0.36	0.4	0.96	0.66	0.51	0.45	0.15	0.73		0.52	0.45	0.19	0.21	-0.24	0.86	0.52	0.63	-0.35	-0.59	0.36	0.15	0.98	0.31	0.79	-0.63
Other Current Assets	0.74	0.93	0.94	0.69	0.62	0.62	0.81	-0.25	0.82	0.52		0.94	0.42	0.34	-0.69	0.84	0.59	0.5	-0.89	-0.95	0.83	0.69	0.64	0.92	0.79	-0.93
Total Liab	0.67	0.98	0.99	0.61	0.71	0.67	0.8	-0.19	0.8	0.45	0.94		0.41	0.3	-0.69	0.81	0.65	0.53	-0.89	-0.97	0.94	0.8	0.58	0.93	0.78	-0.93
Common Stock	0.31	0.38	0.38	0.27	0.34	0.24	0.28	-0.09	0.28	0.19	0.42	0.41		0.21	-0.12	0.27	0.38	-0.2	-0.23	-0.43	0.36	0.25	0.22	0.37	0.4	-0.41
Property Plant Equipment	0.27	0.21	0.25	0.24	0.37	0.32	0.3	-0.12	0.45	0.21	0.34	0.3	0.21		0.06	0.21	0.54	0.22	-0.18	-0.43	0.25	0.01	0.25	0.11	0.43	-0.47
Short Long Term Debt Total	-0.45	-0.76	-0.75	-0.41	-0.43	-0.53	-0.69	-0.02	-0.53	-0.24	-0.69	-0.69	-0.12	0.06		-0.59	-0.06	-0.51	0.87	0.62	-0.61	-0.72	-0.36	-0.78	-0.51	0.56
Net Tangible Assets	0.92	0.78	0.8	0.92	0.71	0.6	0.66	-0.02	0.82	0.86	0.84	0.81	0.27	0.21	-0.59		0.56	0.7	-0.72	-0.86	0.75	0.61	0.91	0.74	0.85	-0.84
Property Plant And Equipment Net	0.65	0.49	0.54	0.6	0.71	0.51	0.69	-0.21	0.77	0.52	0.59	0.65	0.38	0.54	-0.06	0.56		0.41	-0.48	-0.75	0.6	0.18	0.6	0.38	0.77	-0.79
Current Deferred Revenue	0.67	0.49	0.52	0.67	0.59	0.63	0.62	0.09	0.67	0.63	0.5	0.53	-0.2	0.22	-0.51	0.7	0.41		-0.62	-0.58	0.47	0.34	0.69	0.4	0.62	-0.6
Net Debt	-0.61	-0.89	-0.9	-0.55	-0.61	-0.66	-0.9	0.18	-0.76	-0.35	-0.89	-0.89	-0.23	-0.18	0.87	-0.72	-0.48	-0.62		0.86	-0.77	-0.69	-0.51	-0.87	-0.71	0.83
Retained Earnings	-0.79	-0.91	-0.94	-0.74	-0.8	-0.74	-0.85	0.14	-0.9	-0.59	-0.95	-0.97	-0.43	-0.43	0.62	-0.86	-0.75	-0.58	0.86		-0.87	-0.65	-0.71	-0.85	-0.89	0.99
Non Current Assets Total	0.55	0.95	0.94	0.5	0.59	0.48	0.65	-0.23	0.65	0.36	0.83	0.94	0.36	0.25	-0.61	0.75	0.6	0.47	-0.77	-0.87		0.9	0.47	0.9	0.66	-0.8
Non Currrent Assets Other	0.33	0.89	0.85	0.28	0.33	0.32	0.43	-0.18	0.38	0.15	0.69	0.8	0.25	0.01	-0.72	0.61	0.18	0.34	-0.69	-0.65	0.9		0.24	0.89	0.39	-0.54
Cash And Short Term Investments	0.98	0.49	0.53	0.99	0.74	0.61	0.6	0.09	0.83	0.98	0.64	0.58	0.22	0.25	-0.36	0.91	0.6	0.69	-0.51	-0.71	0.47	0.24		0.43	0.87	-0.75
Net Receivables	0.54	0.98	0.96	0.49	0.47	0.47	0.68	-0.25	0.62	0.31	0.92	0.93	0.37	0.11	-0.78	0.74	0.38	0.4	-0.87	-0.85	0.9	0.89	0.43		0.6	-0.78
Common Stock Total Equity	0.94	0.68	0.73	0.9	0.89	0.78	0.85	0.01	0.98	0.79	0.79	0.78	0.4	0.43	-0.51	0.85	0.77	0.62	-0.71	-0.89	0.66	0.39	0.87	0.6		-0.91
Retained Earnings Total Equity	-0.82	-0.85	-0.89	-0.77	-0.83	-0.76	-0.86	0.11	-0.93	-0.63	-0.93	-0.93	-0.41	-0.47	0.56	-0.84	-0.79	-0.6	0.83	0.99	-0.8	-0.54	-0.75	-0.78	-0.91

Click cells to compare fundamentals

Intracellular Account Relationship Matchups

Intracellular fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	251.2M	717.3M	489.9M	754.8M	728.3M	410.9M
Other Current Liab	25.6M	25.8M	37.9M	63.7M	108.5M	113.9M
Total Current Liabilities	36.2M	36.9M	53.4M	83.2M	123.5M	129.7M
Total Stockholder Equity	195.0M	656.9M	417.9M	656.1M	591.4M	366.2M
Accounts Payable	7.4M	5.5M	8.7M	10.4M	11.5M	6.4M
Cash	107.6M	60.0M	92.4M	148.6M	147.8M	74.0M
Other Assets	608.1K	350.7K	86.1K	86K	98.9K	94.0K
Common Stock Shares Outstanding	55.2M	70.4M	81.3M	94.0M	95.9M	55.1M
Short Term Investments	116.4M	597.4M	320.0M	443.3M	350.2M	287.1M
Other Current Assets	6.3M	15.6M	26.8M	46.9M	42.4M	44.6M
Total Liab	56.2M	60.5M	72.0M	98.7M	136.9M	143.7M
Common Stock	5.6K	8.0K	8.2K	9K	10K	6.6K
Property Plant Equipment	2.3M	2.0M	22.6M	1.9M	2.2M	3.0M
Net Tangible Assets	195.0M	656.9M	417.9M	656.1M	754.5M	792.2M
Property Plant And Equipment Net	20.5M	26.3M	22.6M	16.7M	14.6M	9.6M
Net Debt	(84.5M)	(30.9M)	(67.0M)	(128.6M)	(130.8M)	(124.3M)
Retained Earnings	(710.1M)	(937.1M)	(1.2B)	(1.5B)	(1.6B)	(1.5B)
Non Current Assets Total	20.9M	26.4M	22.6M	16.8M	60.5M	63.5M
Cash And Short Term Investments	224.0M	657.4M	412.3M	591.9M	497.9M	388.7M
Common Stock Total Equity	5.6K	8.0K	8.2K	9K	10.4K	5.5K
Retained Earnings Total Equity	(710.1M)	(937.1M)	(1.2B)	(1.5B)	(1.3B)	(1.3B)
Liabilities And Stockholders Equity	251.2M	717.3M	489.9M	754.8M	728.3M	443.0M
Non Current Liabilities Total	20.0M	23.6M	18.7M	15.5M	13.3M	10.0M
Capital Surpluse	905.0M	1.6B	1.6B	2.1B	2.5B	2.6B
Other Stockholder Equity	905.0M	1.6B	1.6B	2.1B	2.2B	2.3B
Property Plant And Equipment Gross	20.5M	26.3M	1.8M	1.9M	14.6M	15.3M
Total Current Assets	230.3M	690.9M	467.3M	738.0M	667.8M	428.9M
Accumulated Other Comprehensive Income	128.3K	480.6K	(363.7K)	(4.2M)	104K	109.2K
Net Invested Capital	195.0M	656.9M	417.9M	656.1M	591.4M	516.9M
Net Working Capital	194.1M	654.1M	413.9M	654.7M	544.3M	508.4M
Capital Stock	5.6K	8.0K	8.2K	9K	10K	8.5K

Currently Active Assets on Macroaxis

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C
MSFT	Microsoft
GM	General Motors

When determining whether Intracellular Th offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intracellular's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intracellular Th Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intracellular Th Stock:

How To Invest In Intracellular

Details

Is Intracellular Stock a good investment?

Details

What is Intracellular's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Intracellular Th. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.87)

Revenue Per Share

6.096

Quarterly Revenue Growth

0.39

Return On Assets

(0.07)

Return On Equity

(0.1)

The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Intracellular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Intracellular Cost Of Revenue vs Income Before Tax Analysis

Cost Of Revenue vs Income Before Tax

Cost Of Revenue vs Income Before Tax Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Income Before Tax

Intracellular fundamental ratios Correlations

Intracellular Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Intracellular fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Liabilities	+ 1.0	Other Current Liab
Total Stockholder Equity	+ 0.99	Total Assets
Total Liab	+ 0.99	Total Current Liabilities
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity
Retained Earnings Total Equity	+ 0.99	Retained Earnings
Cash And Short Term Investments	+ 0.98	Total Assets

Retained Earnings	- 0.97	Total Liab
Retained Earnings	- 0.95	Other Current Assets
Retained Earnings	- 0.94	Total Current Liabilities
Retained Earnings Total Equity	- 0.93	Total Liab
Retained Earnings Total Equity	- 0.93	Other Current Assets
Retained Earnings Total Equity	- 0.93	Common Stock Shares Outstanding